Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$94.54 USD

94.54
205,950

+2.84 (3.10%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $94.49 -0.05 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.

Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip

Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.

Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut

The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.

Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.

Sanghamitra Saha headshot

Can Stocks Enjoy Halloween Effect Despite Rising Rate Fear?

The spooky occasion Halloween can turn into an occasion of angels for Wall Street. Top-ranked sectors like energy, construction, medical and utilities, especially, have the potential to experience a Halloween Effect this year.

Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Up

Thermo Fisher's (TMO) PPI Business System and strong execution by its global team enabled the company to deliver strong financial performance for Q3.

Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates

Amedisys (AMED) delivered earnings and revenue surprises of -9.26% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.

DaVita's (DVA) Latest Partnership to Improve Kidney Care

DaVita's (DVA) new tie-up is likely to enable it to harness Google Cloud's AI and analytics tools to improve care plans and streamline clinical workflows.

ADUS vs. USPH: Which Stock Is the Better Value Option?

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks.com featured highlights Addus HomeCare, Amalgamated Financial, ALLETE, Arcose and Limbach

Addus HomeCare, Amalgamated Financial, ALLETE, Arcose and Limbach have been highlighted in this Screen of The Week article.

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy as Market Woes Compound

The crux of safe investment lies in choosing a company that is not burdened with debt. This is because a debt-free stock is almost impossible to find. You can buy ADUS, AMAL, ALE, ACA and LMB.

Are Investors Undervaluing Addus HomeCare (ADUS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Humana's (HUM) 2024 MA Plans Promise a Wider Set of Benefits

Humana (HUM) aims to expand the reach of its Medicare plans across newer U.S. counties in 2024 through integrating multiple lucrative benefits within them.

ADUS vs. USPH: Which Stock Should Value Investors Buy Now?

ADUS vs. USPH: Which Stock Is the Better Value Option?

Addus HomeCare (ADUS) Q2 Earnings and Revenues Beat Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 7% and 1.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?

Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.

Why Addus HomeCare (ADUS) Could Beat Earnings Estimates Again

Addus HomeCare (ADUS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for Thermo Fisher (TMO) in Q2 Earnings?

Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.

UnitedHealth Group (UNH) Q2 Earnings Beat, Boosts '23 EPS View

UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.

Debanjana Dey headshot

4 Stocks to Hold in a Challenging Outpatient Home Health Industry

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.

Bruker (BRKR) Launches ENRICH-iST Kits and Novel Workflow

Bruker's (BRKR) ENRICH-iST kit is ready to use right out of the box. The workflow is simple to understand and fully automatable.

Teleflex's (TFX) Wattson Temporary Pacing Receives FDA Nod

Teleflex's (TFX) Wattson Temporary Pacing Guidewire offers dual functionality, allowing both valve delivery and ventricular bipolar pacing during TAVR or BAV treatments.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.